$CRL

Parisotto Shannon M sold $1.0M of CRL

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 3,714 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $279.66 ($1.04M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parisotto Shannon M
Published Aug 13, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The disclosed event is an open-market sale by an officer under a pre-arranged 10b5-1 plan, which is generally treated as routine compliance rather than a new fundamental catalyst.

02

Market read

Traders may log the sale for sentiment monitoring, but it is unlikely to drive a material repricing without accompanying company-specific news.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no explanation for the sale, and no concurrent company news, limiting signal strength.

Relevance 5/10Novelty 3/10Timing: filed Aug 13, transaction dated Aug 11

Background

This is an SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc. (CRL).

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

CRL insider Parisotto Shannon M sold 3,714 shares for about $1.04M under a pre-arranged 10b5-1 plan filed on SEC EDGAR.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with an explicit pre-arranged 10b5-1 plan, which reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may watch for follow-on sales or changes in buying activity.

Key entities

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Parisotto Shannon M

    Officer (CEVP, Disc and Safety Assessment) who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRLHigh

Charles River Labs Stock Climbs As Analysts Boost Targets

Charles River Laboratories (CRL) stock rose 11.27% on strong earnings and analyst upgrades. The company reported $1.00B revenue, $150.8M EBITDA, and $148.62M free cash flow. Analysts raised price targets to $320-$357, citing long-term growth plans and margin expansion. CRL's 'Pathway to Purpose' targets 5-7% revenue CAGR and 24% operating margins by 2030.

$CRLHigh

Charles River (CRL) Stock Climbs As Wall Street Turns Bullish

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

$CRLHighAI 8/10

Why is Charles River Laboratories stock surging today?

Charles River Laboratories (CRL) stock rose 5.7% to $293.22 after its Investor Day, where it unveiled a 'Pathway to Purpose' strategy and raised its 2026 financial outlook. The company set 2030 targets of 5-7% annual organic revenue growth and a 24% non-GAAP operating margin, while reaffirming and upgrading its 2026 guidance. The move was driven by company-specific developments, as the broader market declined.

$CRLMed

Why Charles River Laboratories (CRL) Stock Is Trading Up Today

Charles River Laboratories (CRL) shares rose 3.6% after launching rapid cell banking programs, reducing production time by 40% compared to industry standards. The company aims to improve product quality and regulatory readiness. Shares closed at $281.70, up 3% from the previous close. CRL's stock has seen significant volatility, with a 38.1% gain year-to-date.